Bristol-Myers Squibb 4Q Revenues: $7.9 billion (+33%) 4Q Loss: $1.1 billion (earnings were $1.2 billion 4Q18) FY Revenues: $26.1 billion (+16%) FY Earnings: $3.4 billion (-30%) Comments: Eliquis sales were $2.0 billion in the quarter, up 19%. Opdivo sales were $1.8 billion, down 2%. Orencia sales were $792 million in the quarter, up 8%. Sprycel sales were up 2% to $549 million. Yervoy sales were flat at $385 million. Top selling Celgene products include: Revlimid with sales ...